Tyrosinemia is an inherited metabolic disorder that inhibits the body’s ability to process or break down essential amino acids found in common foods that are consumed. Tyrosinemia Type 1 attacks during infancy and is very serious.
Tyrosinemia can be diagnosed through newborn screening, increasing the chance of successful treatment. However, screening doesn’t always happen, resulting in late diagnosis and less efficient and effective treatment.
This is where The Advisory Committee on Heritable Disorder in Newborns and Children comes in. The committee aims to decrease mortality in newborns who have, or are at risk for, heritable disorders. They recommend newborn screening for Tyrosinemia Type 1, among other inherited diseases, is part of every standard newborn screening protocol.
On February 9th, The Advisory Committee on Heritable Disorders in Newborns and Children will have a committee meeting via webinar from 10 am until 3:30 pm.
You can register for the event here.